North America Emerges as the Most Profitable Market for Bleeding Disorder Testing

According to a recent FMI analysis, the Global Bleeding Disorder Testing Market Demand will grow at a 7.2% CAGR from 2023 to 2033. The market is anticipated to be valued at US$ 190 billion by the end of the assessment period. As the prevalence of liver diseases, anaemia, and other blood coagulation problems rises, so will the demand for bleeding disorders testing.

In the affected body location, a clump of platelets and a specific type of blood cell forms. This clot keeps infections out of the bloodstream and prevents blood from draining from the injured area. Testing for bleeding disorders can help determine whether specific clotting factors are present and how long it takes for blood to clot.

Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-15961

The test measures the time it takes for the arteries to contract and platelets in the blood to close the opening. According to the National Haemophilia Foundation, Von Willebrand disease is the most common bleeding disorder, affecting around one in every 100 people, or up to 1% of the US population.

Key Takeaways from the Market Study

• According to FMI, the Global Bleeding Disorder Testing market would grow at a 7.2% CAGR by 2033.
• The global bleeding disorder testing industry is predicted to be worth $ 95 billion.
• The global bleeding disorder testing industry is anticipated to be worth US$ 190 billion.
• North America is expected to be the most profitable market for Bleeding Disorder Testing growth.
• According to Future Market Insights, Asia Pacific is predicted to develop at a CAGR of 6.5% from 2023 to 2033.
• Europe is predicted to increase at a CAGR of 6.9% between 2023 and 2033.
• In the forecast period 2023 to 2033, the diagnostic centres category is estimated to hold the greatest market share for Bleeding Disorder Testing.

“The North American market is expected to expand significantly throughout the projected period. The increase can be attributed to the increased availability of testing devices and the rising number of regulatory approvals,” says an analyst at FMI

Bleeding Disorder Testing Market Report Available At a Discounted Price: https://www.futuremarketinsights.com/request-discount/rep-gb-15961

Bleeding Disorder Testing Market Growth:

Increasing Blood Disorder Prevalence to Improve Maintenance and Performance

Chronic illness includes blood issues. They are also hazardous since they circulate in the blood. The prevalence of conditions such as liver disease, anaemia, and other blood coagulation concerns has increased, as has the demand for bleeding disorders testing. These inherited diseases resulted in a profitable market expansion.

Government Investments in Healthcare Interoperability Have an Impact on the Market

The increasing funding provided by the federal government to encourage the use of these solutions has an additional impact on the sector. Furthermore, rising healthcare spending, advancements in healthcare infrastructure, and rising need for long-term care delivery all benefit the bleeding disorders testing sector, promoting market expansion.

Market Competition:

Key players

1. Siemens Healthcare GmbH
2. F. Hoffmann-La Roche Ltd.
3. Abbott Laboratories
4. Thermo Fisher Scientific Inc.
5. Atlas Medical GmbH
6. Horiba Ltd.
7. Hyphen Bio Med
8. Precision Biologics Incorporated
9. Pfizer Inc.
10. Baxter

Recent Developments

• In March 2021, F. Hoffmann La Roche Ltd. introduced eight new configurations for Cobas pro integrated solutions, with the goal of increasing throughput and testing efficiency.

Customize Your Report Now: https://www.futuremarketinsights.com/customization-available/rep-gb-15961

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Global automotive axle market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Product Type (Reagents & Consumables and Instruments), Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease, Idiopathic Thrombocytopenic Purpura and Others), (Hospitals & Clinics, Diagnostic Centers and Others), across seven major regions (North America, Latin America, Europe, South Asia & Pacific, East Asia and Middle East & Africa).

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs